Research Site

Hoogeveen 7909 AA

1 studies enrolling now · 15 studies all time

What they study most

Acute Coronary Syndrome, Atherothrombosis, Cardiovascular Death, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Type 2, Dyslipidemia, Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD), Heart Failure, High Risk for Cardiovascular Event, Hyperlipidemia, Hyperlipidemia and Mixed Dyslipidemia, Myocardial Infarction

Studies at this site

• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin — Recruiting now
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension — Completed
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 — Completed
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia — Completed
• A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events — Completed
• Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia — Completed
• Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes — Completed
• Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients — Stopped early
• Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus — Completed
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed
• Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) — Completed
• Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications — Completed